{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_7622259_B1","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"196-215-592-552-075","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10826,"type":"PATENT","title":"KU Leuven - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":7336,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8278,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: univ* AND Leuven;
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 3165
Search Applicants and Owners separately: stony brook Uni*; stony brook university. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 13
Search Applicants and Owners separately: univ* AND Leuven;
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 3165
Search Applicants and Owners separately: stony brook Uni*; stony brook university. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 13
(a) detecting the binding activity of vWF in a sample to a soluble form or a portion of glycoprotein 1b(α) (GP1b(α)) that is not associated with a platelet in the presence of ristocetin or a functionally equivalent substance, wherein the soluble form or portion of GP1b(a) is presented by an anti-GP1b(α) antibody;\n
(b) determining an amount of vWF-antigen in said sample;\n
(c) determining a ratio between the binding activity detected under step (a) and the amount of vWF-antigen determined under step (b) for said sample;\n
(d) comparing the ratio obtained under (c) to a reference range; and\n
(e) discriminating between types of von-Willebrand disease based using the comparison result obtained under step (d)."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein detecting the binding activity under step (a) comprises detecting formation of a complex comprising vWF and the soluble form or the portion of GP1b(α)."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said anti-GP1b(α) antibody is bound to a solid support."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein said complex is bound to a solid support by the anti-GP1b(α) antibody."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein detecting the binding activity under step (a) comprises using an anti-vWF antibody."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein detecting the binding activity under step (a) comprises using a heterogeneous or homogeneous assay."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 6, wherein detecting the binding activity under step (a) comprises using an heterogeneous assay selected from the group consisting of enzyme linked immunosorbent assay (ELISA), a radioimmunoassay (RIA), an immunoradiometric assay (IRMA), a fluorescent immunoassay (FIA), a chemiluminescent immunoassay (CLIA) and an electrochemiluminescent immunoassay (ECL)."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 6, wherein detecting the binding activity under step (a) comprises using an homogeneous agglutination assay."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the sample is obtained from blood, serum or plasma of a patient."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the soluble form or the portion of GP1b(α) is a recombinant protein."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said anti-GP1b(α) antibody is a monoclonal antibody, a polyclonal antibody, a synthetic antibody, or a fragment of an antibody."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said anti-GP1b(α) antibody is detectably labeled."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 3, wherein said solid support is selected from a group consisting of plastic, glass, silicon, metal, polystyrene, polyvinyl chloride, polypropylene, polyethylene, polycarbonate, dextran, nylon, amylose, natural or modified cellulose, polyacrylamide, agarose, magnetide and any combinations thereof."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, wherein said solid support comprises a latex bead."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 8, wherein said agglutination is measured by electric field variation, magnetic field variation, turbidimetric variation or light scattering."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein the sample is diluted."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the soluble form or the portion of GP1b(α) comprises an N-terminal domain of GP1b(α)."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the soluble form or the portion of GP1b(α) comprises amino acid residues His1-Val289 of GP1b(α)."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the detecting step (a) permits detecting the binding activity of vWF to the soluble form or the portion of GP1b(α) to a lower limit of 0.0005 U/mL of vWF with a coefficient of variation less than 20%."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the sample is plasma or serum."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein discriminating between types of von-Willebrand disease (vWD) in step (e) comprises discriminating Type 1 vWD from Type 2 vWD."],"number":21,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}